During the progression of Differentiated Thyroid Cancer (DTC), the most frequent and relevant molecular alterations comprise rearrangements of tyrosine kinase receptor genes, such as RET/ PTC and NTRK1 (neurotrophic receptor tyrosine kinase 1), or protein-activating point mutations affect the cellular responses to signals of growth and differentiation signaling pathways, including: RAS, BRAF, PI3K, and oncogenic fusion protein PAX8-PPAR [55, 56]. Here, PAX8 is linked to differentiated thyroid carcinoma.